BDRX.US Biodexa Pharmaceticals

Healthcare Biotechnology USA Stocks
2.40 USD
Close of Nov 13, 2026
2.28 357.60
Market cap
USD 1.26M
P/E
0.0x
P/B
0.05x
ROE
-78.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is BDRX.US undervalued?

Graham number

The Graham number of Biodexa Pharmaceticals cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biodexa Pharmaceticals fundamental analysis

No fundamental analysis for Biodexa Pharmaceticals yet.

Biodexa Pharmaceticals stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biodexa Pharmaceticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in…

Full company profile